

Frank B Furnari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8095396/publications.pdf>

Version: 2024-02-01

103
papers

14,004
citations

25034

57
h-index

31849

101
g-index

112
all docs

112
docs citations

112
times ranked

19474
citing authors

#	ARTICLE	IF	CITATIONS
1	Malignant astrocytic glioma: genetics, biology, and paths to treatment. <i>Genes and Development</i> , 2007, 21, 2683-2710.	5.9	1,952
2	Malignant glioma: genetics and biology of a grave matter. <i>Genes and Development</i> , 2001, 15, 1311-1333.	5.9	1,064
3	PHLPP: A Phosphatase that Directly Dephosphorylates Akt, Promotes Apoptosis, and Suppresses Tumor Growth. <i>Molecular Cell</i> , 2005, 18, 13-24.	9.7	796
4	Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. <i>Nature</i> , 2017, 543, 122-125.	27.8	530
5	Emerging insights into the molecular and cellular basis of glioblastoma. <i>Genes and Development</i> , 2012, 26, 756-784.	5.9	463
6	Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA. <i>Science</i> , 2014, 343, 72-76.	12.6	460
7	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. <i>Genes and Development</i> , 2010, 24, 1731-1745.	5.9	454
8	Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting. <i>Clinical Cancer Research</i> , 2006, 12, 5064-5073.	7.0	440
9	Heterogeneity Maintenance in Glioblastoma: A Social Network. <i>Cancer Research</i> , 2011, 71, 4055-4060.	0.9	386
10	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12867-12872.	7.1	365
11	Circular ecDNA promotes accessible chromatin and high oncogene expression. <i>Nature</i> , 2019, 575, 699-703.	27.8	343
12	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. <i>Nature Reviews Cancer</i> , 2015, 15, 302-310.	28.4	305
13	Cancer-Associated Protein Kinase C Mutations Reveal Kinase's Role as Tumor Suppressor. <i>Cell</i> , 2015, 160, 489-502.	28.9	285
14	An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. <i>Cancer Cell</i> , 2016, 30, 683-693.	16.8	237
15	EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma. <i>Cancer Research</i> , 2009, 69, 4252-4259.	0.9	232
16	PCAF Modulates PTEN Activity. <i>Journal of Biological Chemistry</i> , 2006, 281, 26562-26568.	3.4	183
17	A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma. <i>PLoS Genetics</i> , 2009, 5, e1000374.	3.5	179
18	EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. <i>Molecular Cell</i> , 2015, 60, 307-318.	9.7	161

#	ARTICLE	IF	CITATIONS
19	NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. <i>Nature</i> , 2019, 569, 570-575.	27.8	153
20	Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. <i>Cancer Research</i> , 2002, 62, 6764-9.	0.9	152
21	MicroRNA-138 Modulates DNA Damage Response by Repressing Histone H2AX Expression. <i>Molecular Cancer Research</i> , 2011, 9, 1100-1111.	3.4	146
22	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. <i>Cancer Cell</i> , 2018, 34, 163-177.e7.	16.8	145
23	Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6505-6510.	7.1	141
24	Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. <i>Journal of Clinical Investigation</i> , 2011, 121, 161-173.	8.2	141
25	Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients. <i>Cancer Research</i> , 2009, 69, 6889-6898.	0.9	136
26	Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. <i>Cell Metabolism</i> , 2019, 30, 525-538.e8.	16.2	130
27	Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. <i>Oncotarget</i> , 2014, 5, 882-893.	1.8	127
28	Epidermal growth factor receptor targeting and challenges in glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 914-918.	1.2	117
29	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. <i>Chinese Journal of Cancer</i> , 2011, 30, 5-12.	4.9	116
30	A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma. <i>PLoS Genetics</i> , 2013, 9, e1003253.	3.5	114
31	Immunohistochemical analysis of the mutant epidermal growth factor, $\hat{1}$ EGFR, in glioblastoma. <i>Brain Tumor Pathology</i> , 2004, 21, 53-56.	1.7	112
32	Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2703-2706.	7.1	109
33	Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. <i>Cancer Cell</i> , 2008, 13, 355-364.	16.8	109
34	Alix/AIP1 Antagonizes Epidermal Growth Factor Receptor Downregulation by the Cbl-SETA/CIN85 Complex. <i>Molecular and Cellular Biology</i> , 2004, 24, 8981-8993.	2.3	108
35	Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFR $\hat{1}$ -stimulated glioma tumorigenesis in mice and humans. <i>Journal of Clinical Investigation</i> , 2011, 121, 4670-4684.	8.2	105
36	Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor $\hat{1}$ -Specific Antibody Generates Enhanced Antitumor Activity. <i>Clinical Cancer Research</i> , 2005, 11, 6390-6399.	7.0	103

#	ARTICLE	IF	CITATIONS
37	PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. <i>Oncogene</i> , 1999, 18, 3936-3943.	5.9	102
38	Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. <i>Cancer Cell</i> , 2019, 35, 504-518.e7.	16.8	102
39	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14164-14169.	7.1	97
40	PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. <i>Nature Communications</i> , 2017, 8, 15223.	12.8	94
41	MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 5768-5773.	7.1	91
42	In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 9418-9423.	7.1	90
43	Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3018-3023.	7.1	88
44	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. <i>Carcinogenesis</i> , 2013, 34, 725-738.	2.8	86
45	The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc ⁻ . <i>Cancer Research</i> , 2016, 76, 2954-2963.	0.9	84
46	EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. <i>Journal of Clinical Investigation</i> , 2014, 124, 3741-3756.	8.2	82
47	Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 370-375.	7.1	79
48	IGF-1 receptor signaling in a prostatic cancer cell line with a PTEN mutation. <i>Oncogene</i> , 2000, 19, 2687-2694.	5.9	75
49	The Protein Tyrosine Phosphatase TCPTP Suppresses the Tumorigenicity of Glioblastoma Cells Expressing a Mutant Epidermal Growth Factor Receptor. <i>Journal of Biological Chemistry</i> , 2001, 276, 46313-46318.	3.4	66
50	The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. <i>Cancer Cell</i> , 2006, 9, 379-390.	16.8	65
51	Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. <i>Journal of Experimental Medicine</i> , 2011, 208, 2657-2673.	8.5	65
52	The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization. <i>Clinical Cancer Research</i> , 2007, 13, 1911-1925.	7.0	64
53	Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach. <i>Cell Cycle</i> , 2007, 6, 2750-2754.	2.6	63
54	Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2616-2621.	7.1	63

#	ARTICLE	IF	CITATIONS
55	Integrin $\alpha 5 \beta 1$ Internalizes Zika Virus during Neural Stem Cells Infection and Provides a Promising Target for Antiviral Therapy. <i>Cell Reports</i> , 2020, 30, 969-983.e4.	6.4	63
56	Blockade of a Laminin-411 $\alpha 6 \beta 1$ Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk. <i>Cancer Research</i> , 2019, 79, 1239-1251.	0.9	61
57	PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4339-4344.	7.1	60
58	Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy. <i>PLoS ONE</i> , 2010, 5, e10767.	2.5	59
59	Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. <i>Cancer Research</i> , 2014, 74, 1429-1439.	0.9	59
60	Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 15984-15989.	7.1	54
61	Glioblastoma cellular cross-talk converges on NF- κ B to attenuate EGFR inhibitor sensitivity. <i>Genes and Development</i> , 2017, 31, 1212-1227.	5.9	53
62	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. <i>Science Signaling</i> , 2014, 7, pe15.	3.6	50
63	YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity. <i>Oncogene</i> , 2018, 37, 5492-5507.	5.9	49
64	A Urokinase Receptor $\alpha 3 \beta 1$ Bim Signaling Axis Emerges during EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma. <i>Cancer Research</i> , 2015, 75, 394-404.	0.9	48
65	The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas. <i>Clinical Cancer Research</i> , 2013, 19, 5722-5732.	7.0	46
66	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10009-10018.	7.1	46
67	Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. <i>Nature Communications</i> , 2020, 11, 550.	12.8	45
68	Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. <i>Cancer Biology and Medicine</i> , 2013, 10, 192-205.	3.0	45
69	Decoy for microRNAs. <i>Nature</i> , 2010, 465, 1016-1017.	27.8	44
70	Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of $\alpha 3 \beta 1$ EGFR. <i>Journal of Proteome Research</i> , 2011, 10, 1343-1352.	3.7	44
71	Nuclear EGFRvIII $\alpha 3 \beta 1$ STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-2 promoter. <i>International Journal of Cancer</i> , 2013, 132, 509-520.	5.1	41
72	Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. <i>Molecular BioSystems</i> , 2010, 6, 1227.	2.9	40

#	ARTICLE	IF	CITATIONS
73	Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. <i>Journal of Controlled Release</i> , 2016, 244, 14-23.	9.9	40
74	SETA: A novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. <i>Neuro-Oncology</i> , 2000, 2, 6-15.	1.2	38
75	Mechanisms of stearyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. <i>Science Advances</i> , 2021, 7, .	10.3	38
76	Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. <i>Cell Reports</i> , 2021, 37, 109957.	6.4	38
77	Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. <i>Journal of Cell Science</i> , 2011, 124, 2938-2950.	2.0	35
78	Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas. <i>EBioMedicine</i> , 2020, 55, 102736.	6.1	35
79	PI3K ^{Î³} inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	33
80	Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin. <i>Autophagy</i> , 2018, 14, 1845-1846.	9.1	30
81	SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability. <i>Genes and Development</i> , 2020, 34, 1316-1329.	5.9	30
82	Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development. <i>Neuro-Oncology</i> , 2018, 20, 1310-1320.	1.2	27
83	PTEN: A Novel Anti-oncogenic Function Independent of Phosphatase Activity. <i>Cell Cycle</i> , 2005, 4, 540-542.	2.6	26
84	FHL2 interacts with EGFR to promote glioblastoma growth. <i>Oncogene</i> , 2018, 37, 1386-1398.	5.9	25
85	PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1072-1086.	1.2	23
86	Molecular Biology of Malignant Degeneration of Astrocytoma. <i>Pediatric Neurosurgery</i> , 1996, 24, 41-49.	0.7	16
87	Escape from targeted inhibition: The dark side of kinase inhibitor therapy. <i>Cell Cycle</i> , 2010, 9, 1661-1662.	2.6	12
88	Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors. <i>Neuro-Oncology</i> , 2021, 23, 400-411.	1.2	11
89	Intron 1â€™Mediated Regulation of <i>EGFR</i> Expression in EGFR-Dependent Malignancies Is Mediated by AP-1 and BET Proteins. <i>Molecular Cancer Research</i> , 2019, 17, 2208-2220.	3.4	10
90	Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. <i>Oncotarget</i> , 2015, 6, 11751-11767.	1.8	9

#	ARTICLE	IF	CITATIONS
91	<i>TERT</i> promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening <i>in vivo</i> . <i>Neuro-Oncology</i> , 2022, 24, 2063-2075.	1.2	9
92	EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration. <i>Journal of Cell Science</i> , 2020, 133, .	2.0	8
93	Genome Engineering Evolves Brain Tumor Modeling. <i>Neurologia Medico-Chirurgica</i> , 2020, 60, 329-336.	2.2	7
94	Fluorescence Molecular Tomography for <i>In Vivo</i> Imaging of Glioblastoma Xenografts. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	4
95	A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas. <i>Frontiers in Oncology</i> , 2021, 11, 652133.	2.8	4
96	The impact of phosphorylated PTEN at threonine 366 on cortical connectivity and behaviour. <i>Brain</i> , 2022, 145, 3608-3621.	7.6	4
97	The PTEN/PI3 Kinase Pathway in Human Glioma. , 2009, , 315-357.		3
98	When less is more: Gaining power through gene rearrangement of amplified <i>EGFR</i> . <i>Oncotarget</i> , 2019, 10, 2116-2117.	1.8	1
99	ATPS-86MUTATIONS IN THE EGF RECEPTOR EXTRACELLULAR DOMAIN REVEAL AN UNTETHERED TRANSITIONAL STATE WHICH MEDIATES mAb806 BINDING. <i>Neuro-Oncology</i> , 2015, 17, v37.3-v37.	1.2	0
100	CBIO-04DAXX INHIBITION SUPPRESSES TUMOR GROWTH IN PTEN-DEFICIENT HUMAN GLIOBLASTOMAS. <i>Neuro-Oncology</i> , 2015, 17, v55.4-v55.	1.2	0
101	HGG-12. HUMAN IPSC-DERIVED H3.3K27M NEUROSPHERES: A NOVEL MODEL FOR INVESTIGATING DIPG PATHOGENESIS AND DRUG RESPONSE. <i>Neuro-Oncology</i> , 2021, 23, i19-i20.	1.2	0
102	OTEH-9. scRNA sequencing of proneural GBM avatar model reveals acquisition of oncogenic transcriptional programming and infers a developmental path towards a genomically unstable state. <i>Neuro-Oncology Advances</i> , 2021, 3, ii12-ii12.	0.7	0
103	Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. <i>Journal of Cell Biology</i> , 2011, 195, i10-i10.	5.2	0